StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) stock

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.13−0.39 (-0.32%)

Close on Nov 18, 2026Market cap $10.34BP/E –Yield –

Kymera Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Kymera Therapeutics's price to sales ratio was 106.3× on Nov 11, 2026, against 111.3× a year earlier. Over the last 5 years it ranged from 11.6× to 189.5×, with a median of 34.6×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026106.3×−21.3
2025Dec 31, 2025127.6×+97.9
2024Dec 31, 202429.7×−0.4
2023Dec 29, 202330.1×+0.4
2022Dec 30, 202229.7×−16.5
2021Dec 31, 202146.3×−73.1
2020Dec 31, 2020119.4×–

More Kymera Therapeutics figures

See a number that looks wrong?